Holen Sie sich die Stockscreener-App
576.03
1.56%
8.87
Vorhandelsmarkt:
573.28
-2.75
-0.48%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$567.16
Offen:
$562.85
24-Stunden-Volumen:
1.91M
Relative Volume:
0.94
Marktkapitalisierung:
$93.74B
Einnahmen:
$43.74B
Nettoeinkommen (Verlust:
$6.58B
KGV:
33.28
EPS:
17.3072
Netto-Cashflow:
$6.11B
1W Leistung:
-1.78%
1M Leistung:
+6.89%
6M Leistung:
+39.79%
1J Leistung:
+14.91%
1-Tages-Spanne:
$556.46
$578.22
1-Wochen-Bereich:
$556.46
$598.51
52-Wochen-Spanne:
$385.46
$610.97
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
576.03 | 213.09B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
225.51 | 155.71B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
A
Agilent Technologies Inc
|
143.84 | 40.97B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
MTD
Mettler Toledo International Inc
|
1,396.45 | 28.37B | 3.87B | 829.75M | 847.84M | 39.48 |
|
WAT
Waters Corp
|
376.63 | 22.50B | 2.91B | 622.64M | 620.14M | 10.48 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development - BioSpace
Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs - citybiz
Is Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock attractive for growth funds2025 Key Lessons & AI Forecasted Entry and Exit Points - newser.com
Why Thermo Fisher chose Philly for its new East Coast collaboration center for biotech startups - The Business Journals
Thermo Fisher targets early-stage CGT bottlenecks with new Philadelphia hub - rdworldonline.com
These 3 Stocks Are Using Buybacks to Signal Market Confidence - Investing.com
Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Philadelphia - Contract Pharma
These 3 Stocks Are Using Buybacks to Signal Market Confidence - Finviz
Monster Beverage, UnitedHealth, Thermo Fisher Scientific And More: CNBC's 'Final Trades' - Benzinga
Thermo Fisher Scientific Digital Transformation Strategy Analysis Report 2025: Accelerators, Incubators, and Other Innovation ProgramsResearchAndMarkets.com - Bluefield Daily Telegraph
Moody’s upgrades Thermo Fisher Scientific to A2, outlook stable - Investing.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Is a Favorite Amongst Institutional Investors Who Own 89% - 富途牛牛
Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Myasthenia Gravis, a Rare Autoimmune Disorder - The AI Journal
Thermo Fisher Scientific launches CorEvitas clinical registry in myasthenia gravis - PharmaLive
Will Thermo Fisher Scientific Inc. (TN8) stock split increase liquidityMarket Movement Recap & Risk Controlled Stock Alerts - newser.com
Is Thermo Fisher Scientific Inc. (TN8) stock expanding market penetrationDollar Strength & Fast Gain Stock Trading Tips - newser.com
Is Thermo Fisher Scientific Inc. (TN8) stock considered safe havenJuly 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Can Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock expand revenue streamsTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Thermo Fisher Scientific Inc. (TN8) stock supported by strong fundamentalsWeekly Earnings Recap & Real-Time Stock Price Movement Reports - newser.com
How Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock gains from tech spendingJuly 2025 Snapshot & Free Technical Pattern Based Buy Signals - newser.com
How robust is Thermo Fisher Scientific Inc stock financial positionAnalyst Upgrade & Community Verified Watchlist Alerts - newser.com
Is Thermo Fisher Scientific Inc stock in buy zone after pullbackDividend Hike & Daily Chart Pattern Signal Reports - newser.com
Insider Sell: Lisa Britt Sells Shares of Thermo Fisher Scientifi - GuruFocus
Will Thermo Fisher Scientific Inc stock outperform benchmarks2025 Top Decliners & Safe Swing Trade Setups - newser.com
Rx Rundown: Metagenomi, Chiesi, Thermo Fisher Scientific and more - Medical Marketing and Media
Thermo Fisher Scientific Insider Sold Shares Worth $2,756,920, According to a Recent SEC Filing - MarketScreener
Will Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock hit analyst forecastsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
Why Thermo Fisher Scientific Inc. (TN8) stock remains top ratedTrade Signal Summary & Risk Controlled Stock Alerts - Fundação Cultural do Pará
The Zacks Analyst Blog Highlights NVIDIA, Micron Technology and Thermo Fisher Scientific - Nasdaq
If You Invested $1000 in Thermo Fisher Scientific 10 Years Ago, This Is How Much You'd Have Now - Yahoo Finance
Will Thermo Fisher Scientific Inc. stock recover faster than peersQuarterly Earnings Report & Verified Trade Idea Suggestions - newser.com
Thermo Fisher Scientific (TMO): Assessing Valuation After a 10% Monthly Share Price Surge - Yahoo Finance
How dovish Fed policy supports Thermo Fisher Scientific Inc. (TN8) stock2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Why Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock signals breakout potentialWeekly Profit Analysis & Consistent Growth Equity Picks - newser.com
Is Thermo Fisher Scientific Inc. (TN8) stock among top earnings playsJuly 2025 EndofMonth & Intraday High Probability Alerts - newser.com
Fund Update: 127,576 THERMO FISHER SCIENTIFIC (TMO) shares added to First Pacific Advisors, LP portfolio - Quiver Quantitative
Top Research Reports for NVIDIA, Micron Technology & Thermo Fisher - Yahoo Finance
Why analysts recommend Thermo Fisher Scientific Inc. (Common Stock) (TN80) stockJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Can Thermo Fisher Scientific Inc stock attract ESG investmentsWeekly Trade Recap & Fast Moving Market Watchlists - newser.com
Are Wall Street Analysts Predicting Thermo Fisher Scientific Stock Will Climb or Sink? - Barchart.com
Thermo Fisher Scientific Receives 510(k) Clearance in the United States for EXENT System* to Aid in the Diagnosis of Multiple Myeloma - BioSpace
Visual analytics tools that track Thermo Fisher Scientific Inc. performanceQuarterly Portfolio Report & Expert Curated Trade Setups - newser.com
Will Thermo Fisher Scientific Inc. (TN8) stock sustain bullish trend into 2025Take Profit & Verified Momentum Stock Ideas - newser.com
Finalists in the Thermo Fisher JIC explore biomimicry with SERC - societyforscience.org
Thermo Fisher Scientific Receives 510(K) Clearance in the United States for EXENT System to Aid in the Diagnosis of Multiple Myeloma - MarketScreener
Thermo Fisher Scientific Says US FDA Clears Exent System for Multiple Myeloma Diagnosis - MarketScreener
Thermo Fisher’s new diagnostic system for multiple myeloma gets FDA clearance - Investing.com India
Thermo Fisher (NYSE: TMO) receives FDA 510(k) for EXENT M-protein detection for myeloma - Stock Titan
Why analysts remain bullish on Thermo Fisher Scientific Inc. stock2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
Should Thermo Fisher's (TMO) New $5 Billion Buyback Change Views on Its Capital Allocation Priorities? - simplywall.st
Why Thermo Fisher Scientific Inc. stock is rated strong buyJuly 2025 Opening Moves & Expert Verified Stock Movement Alerts - newser.com
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.30%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):